stocktrademan
10 years ago
$TSPT recent news/filings
bullish 10-15% in a week or more longer term
## source: finance.yahoo.com
Thu, 03 Jul 2014 18:35:33 GMT ~ TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
read full: http://biz.yahoo.com/e/140703/tspt8-k.html
*********************************************************
Wed, 02 Jul 2014 05:00:23 GMT ~ Paratek Pharmaceuticals signs merger agreement with NASDAQ-listed Transcept Pharmaceuticals
[at noodls] - NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA Media Release Zug, 2 July 2014 Paratek Pharmaceuticals signs merger agreement with NASDAQ-listed Transcept Pharmaceuticals Paratek Pharmaceuticals, ...
read full: http://www.noodls.com/view/A7D6234787265D35C0D83BC41DB551F05BC16A65
*********************************************************
Tue, 01 Jul 2014 20:12:14 GMT ~ TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
read full: http://biz.yahoo.com/e/140701/tspt8-k.html
*********************************************************
Tue, 01 Jul 2014 10:30:00 GMT ~ Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
[GlobeNewswire] - BOSTON -- Paratek Pharmaceuticals, Inc., today announced that Michael F. Bigham, Partner at Abingworth LLP, has been appointed as Chairman of the Board of Directors and Chief Executive Officer. In addition, ...
read full: http://finance.yahoo.com/news/paratek-appoints-michael-bigham-chairman-103000860.html
*********************************************************
Tue, 01 Jul 2014 10:15:00 GMT ~ Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement
[PR Newswire] - BOSTON, Mass., and POINT RICHMOND, Calif., July 1, 2014 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today that they have entered into a definitive merger agreement under which the stockholders of Paratek will become the majority owners of Transcept and the operations of Transcept and Paratek will be combined. As part of the proposed transaction, new investors (including The Baupost Group, Abingworth LLP, and other institutional investors); Glenn Oclassen, Chief Executive Officer and Chairman of the Transcept Board, commented: "Following Transcept's recent June 3, 2014 special cash dividend of approximately $25.4 million, this transaction with Paratek reflects the continued commitment of Transcept's Board of Directors and management team to deliver value to Transcept's stockholders. Under the proposed transaction, Transcept's stockholders will maintain a meaningful equity ownership stake in Transcept, which will refocus its operations as a late-stage therapeutics company with product candidates we believe possess significant commercial potential. The transaction also provides for our stockholders an additional special cash dividend and the opportunity to realize any upside potential from our INTERMEZZO and TO-2070 assets."
read full: http://finance.yahoo.com/news/transcept-pharmaceuticals-paratek-pharmaceuticals-sign-101500418.html
*********************************************************
$TSPT charts
basic chart ## source: stockcharts.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$TSPT company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/TSPT/company-info
Ticker: $TSPT
OTC Market Place: Not Available
CIK code: 0001178711
Company name: Transcept Pharmaceuticals, Inc.
Incorporated In:
$TSPT share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$TSPT extra dd links
Company name: Transcept Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TSPT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TSPT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TSPT+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/news - http://finance.yahoo.com/q/h?s=TSPT+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TSPT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TSPT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TSPT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Transcept+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Transcept+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Transcept+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TSPT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178711&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TSPT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TSPT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TSPT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TSPT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TSPT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TSPT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TSPT+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TSPT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TSPT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TSPT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TSPT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TSPT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TSPT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TSPT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TSPT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TSPT
$TSPT DD Notes ~ http://www.ddnotesmaker.com/TSPT
a11k
surf1944
10 years ago
2:18AM Transcept Pharma provides update on key initiatives to increase shareholder value (TSPT) 3.52 : Co provides an update to the key initiatives being pursued to increase stockholder value.
The Transcept Board and management team have taken, or are undertaking, the following steps:
In November 2013 co announced the reduction of 6 employees, or ~43% of workforce. In connection with this restructuring, Thomas Soloway, Executive Vice President and Chief Operating Officer, notified the Company that he would resign effective December 31, 2013. With these combined changes, co expects that headcount will be reduced by ~50% and our annual payroll and benefits expense will be reduced by ~$1.23 mln, or 37% of the annual Transcept payroll.
Effective December 31, 2013, Glenn Oclassen, President and Chief Executive Officer, will assume the role of Chairman of the Board and Chief Executive Officer. Concurrently, Kirk Raab, the Company's current Chairman of the Board, will move to the position of Lead Independent Director. Christopher Ehrlich, a longstanding member of the Transcept Board of Directors, will resign from the Board effective December 31, 2013. This restructuring is expected save the Company ~$180,000 on an annualized basis, or 36% of its board governance costs.
Co is continuing our work with Leerink Swann, co's previously announced financial and strategic advisor, to explore a range of alternatives to enhance stockholder value, including a sale of the Company, a business combination, partnership opportunities and distribution of all or a significant amount of cash to stockholders. In particular, co is actively seeking a merger partner and intend to continue this effort into the first quarter of 2014, while continuing to remain open to all stockholder value enhancing opportunities. Co is evaluating a range of alternatives, some of which may result in a transaction with a partial distribution of cash to stockholders concurrent with the transaction. If we cannot identify a transaction in the first quarter 2014, co intends to proceed with a liquidation of the Company.
Co will continue to develop TO-2070, our DHE product candidate for the treatment of acute migraine, through the completion of preclinical safety studies. Co believesthat the continued development of TO-2070 through a successful completion of pre-clinical safety studies will add value to the asset that may be recognized in a potential transaction. Given the timing of the strategic process described above, co does not intend to initiate a Phase 1 human pharmacokinetic study.
Co continues to work with Purdue Pharma, our U.S. marketing partner for Intermezzo, to develop and implement strategies to maximize the value of Intermezzo.
surf1944
11 years ago
7:31AM Transcept Pharma sets special stockholder meeting for Dec 19, 2013; co continues to explore strategic alternatives (TSPT) 3.37 : Co announced that it will hold a special meeting of stockholders on Dec 19, 2013. The meeting arises from a request from a stockholder group that includes: Roumell Asset Management, Retrophin and SC Fundamental Value Fund. This stockholder group is seeking to remove four of the seven current members of the Transcept Board of Directors and to vote on a non-binding resolution calling on the Board to eliminate the Tax Benefit Preservation Plan that the Transcept Board unanimously adopted on Sep 13, 2013 to protect the value of Transcept's cumulative net operating loss carry forwards ("NOLs"). As previously disclosed, the NOLs may have meaningful value to all Transcept stockholders in the future, either to shelter future income or in connection with a strategic transaction.
The co believes that the special meeting request is deficient in a number of respects. However, rather than forcing the stockholder group to revise the request, the Board will call the special meeting to allow all stockholders to make a fully informed decision on these matters. The Transcept Board has established a Nov 5, 2013 record date for stockholders entitled to vote at the special meeting. In contrast to the Board's ongoing exploration of strategic alternatives and other initiatives to create value for all stockholders, the co believes that the objective of this stockholder group is to seize control of Transcept without paying full and fair value to all stockholders.
surf1944
11 years ago
1:38AM Transcept Pharma comments on new FDA Dosage reduction requirements for Zolpidem based prescription sleep aids administered at bedtime (TSPT) 5.76 : The FDA is requiring that the manufacturers of certain zolpidem based prescription sleep aids such as Ambien and Ambien CR, and generic versions of these products, reduce the recommended dose. FDA has informed the manufacturers of these products that the recommended dose of zolpidem at bedtime for women should be lowered from 10 mg to 5 mg for immediate-release products such as Ambien, and from 12.5 mg to 6.25 mg for extended-release products such as Ambien CR. FDA also informed the manufacturers that, for men, the labeling should recommend that health care professionals consider prescribing the lower doses 5 mg for immediate-release products and 6.25 mg for extended-release products.
The FDA announcement further states, "The recommended doses of Intermezzo, a lower dose zolpidem product approved for middle-of-the-night awakenings, are not changing. At the time of Intermezzo's approval in November 2011, the label already recommended a lower dosage for women than for men." Co states: "We are pleased that this action by FDA confirms the recommended dose of Intermezzo at 3.5 mg in men and 1.75 mg in women for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep, so long as they have at least 4 hours of remaining bedtime."
mlkrborn
11 years ago
Transcept Pharmaceuticals announces that a Phase 2 clinical trial of TO-2061 as adjunctive therapy for obsessive compulsive disorder did not meet primary endpoint (TSPT) 5.16 : Co announced initial top-line results from its Phase 2 clinical trial evaluating the efficacy and safety of TO-2061 (ondansetron oral tablets 0.5 mg and 0.75 mg) in patients with obsessive compulsive disorder (OCD) who had not adequately responded to treatment with approved first-line therapies.
The data from the trial showed that TO-2061 did not meet the primary efficacy endpoint to demonstrate an improvement in OCD symptoms versus placebo. Transcept expects to complete the remaining protocol-specified analyses in early 2013 and will make a determination on any future development of TO-2061 after further review of the data.
"It is disappointing that the Phase 2 trial of TO-2061 did not meet its primary endpoint, in particular for those patients suffering from treatment resistant OCD," said Glenn Oclassen, President and Chief Executive Officer of Transcept. "Once we have reviewed the full data set, we will determine next steps, if any, in the clinical development program for TO-2061 for the adjunctive treatment of OCD."
... stock is halted.
surf1944
12 years ago
Transcept Pharmaceuticals Announces Listing of New U.S. Patent for Intermezzo in FDA's Orange Book
PR NewswirePress Release: Transcept Pharmaceuticals, Inc. – Tue, Aug 21, 2012 4:40 PM EDT
POINT RICHMOND, Calif., Aug. 21, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (TSPT) today announced that the U.S. Food and Drug Administration has listed U.S. Patent No. 8,242,131 (the '131 patent) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or "Orange Book." This patent, which was issued by the United States Patent and Trademark Office (USPTO) on August 14, 2012, includes claims directed to methods of treating middle-of-the-night insomnia with low doses of zolpidem. The '131 patent will expire no sooner than 2029.
As part of the collaboration agreement between Purdue Pharmaceutical Products L.P. (Purdue) and Transcept, Transcept is eligible to receive a $10 million milestone payment from Purdue in connection with the '131 patent being listed in the Orange Book. Pursuant to this agreement, Transcept is also eligible to receive up to an additional $70 million in milestone payments related to the achievement of certain U.S. net sales targets of Intermezzo, as well as a royalty on U.S. net sales of Intermezzo that ranges from the mid-teens to the mid-20% level.
This patent adds to the Intermezzo intellectual property portfolio, which includes two previously issued U.S. patents that are currently listed in the Orange Book. In addition, the USPTO issued a Notice of Allowance on July 18, 2012, for an Intermezzo patent application directed to compositions for treating middle-of-the-night insomnia. Intermezzo was also granted three years of Hatch-Waxman regulatory exclusivity by the FDA.
mlkrborn
12 years ago
Transcept Pharma announces listing of new U.S. patent for Intermezzo in FDA's Orange Book (TSPT) 5.65 +0.31 : Co announced that the FDA has listed U.S. Patent No. 8,242,131 (the '131 patent) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or "Orange Book." This patent, which was issued by the United States Patent and Trademark Office (USPTO) on August 14, 2012, includes claims directed to methods of treating middle-of-the-night insomnia with low doses of zolpidem. The '131 patent will expire no sooner than 2029. As part of the collaboration agreement between Purdue Pharmaceutical Products L.P. and Transcept, Transcept is eligible to receive a $10 million milestone payment from Purdue in connection with the '131 patent being listed in the Orange Book. Pursuant to this agreement, Transcept is also eligible to receive up to an additional $70 million in milestone payments related to the achievement of certain U.S. net sales targets of Intermezzo, as well as a royalty on U.S. net sales of Intermezzo that ranges from the mid-teens to the mid-20% level.
manny t
12 years ago
TSPT,
Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
Empire Asset Management Company, a FINRA member (143007), initiated coverage today on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT) with a buy rating and 12 month price target $12.50.
SOURCE Empire Asset Management Co.
Manny
manny t
12 years ago
Just saw this news.maybe the company will give information on how their new sleeping pill is doing.
Transcept Pharmaceuticals to Present at the JMP Securities Healthcare Conference
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the JMP Securities Healthcare Conference in New York on July 12, 2012 at 4:00 p.m. ET.
A live audio webcast and replay of this presentation may be accessed at http://wsw.com/webcast/jmp18/tspt/ and on the Transcept Investor webpage at www.transcept.com.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Contact:Transcept Pharmaceuticals, Inc.Greg MannSr. Director, Corporate Communications(510) 215-3567gmann@transcept.com
Manny
surf1944
12 years ago
Transcept Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Press Release: Transcept Pharmaceuticals, Inc. – Fri, Jun 1, 2012 7:35 AM EDT
POINT RICHMOND, Calif., June 1, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the Jefferies 2012 Global Healthcare Conference in New York on June 7, 2012 at 1:30 p.m. ET.
A live audio webcast and replay of this presentation may be accessed at http://wsw.com/webcast/jeff68/tspt/ and on the Transcept Investor webpage at www.transcept.com.
manny t
12 years ago
Transcept Pharmaceuticals to Report First Quarter 2012 Financial Results and Host Conference Call on May 14, 2012
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, May 14, 2012, at 4:30 p.m. Eastern Time to discuss its first quarter 2012 financial results. The conference call will follow the release of the Transcept first quarter 2012 financial results after the close of market that day.
Conference Call Information Date: Monday, May 14, 2012 Time: 4:30 p.m. ET Dial-in (U.S.): 877-638-4558 Dial-in (International): 914-495-8537
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through July 31, 2012.
A telephone replay of the conference call will be available shortly after the conclusion of the call through May 19, 2012. The replay telephone number is 855-859-2056 (U.S.) or 404-537-3406 (International), replay passcode: 77576088.
About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Contact:Transcept Pharmaceuticals, Inc.Greg MannSr. Director, Corporate Communications(510) 215-3567gmann@transcept.com
SOURCE Transcept Pharmaceuticals, Inc.
Register to chat with like-minded investors on our interactive forums.
bigboard
6 months ago
Penny Roger$
11 years ago
Hot Features
Premium
